Microbix presents the results of its HPV product at EUROGIN

Microbix Biosystems Inc.

QAPs Supporting High-Risk Human Papillomavirus Testing

MISSISSAUGA, Ontario, April 08, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it will present the performance results of its quality assessment products (“QAP™”) supporting the human papilloma virus (“HPV”) molecular diagnostic screening tests at the European Organization for Genital Infections and Neoplasms Research 2022 Annual Congress (“EUROGIN”) which will take place in Düsseldorf, Germany, from April 10 to 12, 2022.

At EUROGIN, Microbix will be exhibiting alongside leading diagnostic companies that provide screening tests for the detection of HPV infections. Microbix has QIPs to support testing for eight (8) high-risk HPV types available for sale in Canada, Europe, the United States, and other commercially significant jurisdictions under its “REDx™ Commands” or “PROCEEDx™ brand names. Most sexually active adults are infected with one or more types of HPV, and its high-risk types are well-known and common causes of human cancers. Testing for high-risk HPV infections provides important preventative health information and requires validated, regulated, third-party test controls to ensure accuracy.

Microbix will also review the performance of its high-risk HPV multiplex QAPs in supporting test quality management for high-risk HPV types through comprehensive and extensive genotyping testing. His poster presentation is titled “Performing extensive and comprehensive genotyping testing using a novel high-risk HPV multiplex panel.“The poster details the performance of high-risk HPV multiplex QAPs in supporting BD Onclarity™ testing and Microbix thanks Becton Dickinson Life Sciences for their assistance in planning and performing these assessments. The poster will be available on the Microbix website (https://microbix.com) and from EUROGIN after its presentation.

Additionally, Microbix is ​​proud to announce its collaboration with Copan Italia SpA (“Copan®”) and key opinion leaders from VCS Pathology (Victoria, Australia) to advance the molecular diagnosis of HPV by self-sampling (“MDx”) tests. A presentation entitled “Validation of MSwab™ medium for the elution of FLOQSwabs® for the detection of human papillomavirus (HPV) on six PCR-based commercial HPV tests » will demonstrate new self-sampling tools for HPV testing programs. Allowing patients to collect samples in private and convenient locations should accelerate the widespread adoption of MDx-based HPV testing programs. Microbix is ​​proud to be a strategic partner of Copan and to offer solutions focused on HPV”PROCEED™FLOQ®“(RUO) and prospective”REDx™FLOQ®” (IVD) QAPs to support self-collection screening programs worldwide. Purchase requests for Microbix QAP™ can be emailed to customer.service@microbix.com.

Prior to the pandemic, health systems were preparing MDX-based HPV screening programs to identify people at risk years before cancer cells could be detected by pathology. These programs were delayed due to MDx’s ability to be co-opted for COVID testing, but are now being reconsidered as COVID becomes rampant. Microbix believes that many high-risk HPV infections and resulting cancers have gone undiagnosed and are pleased to support the resumption and expansion of MDx screening programs.

About Microbix Biosystems
Microbix develops proprietary biological technology solutions for human health and well-being, with over 100 skilled employees and sales approaching C$2.0 million per month. It manufactures a wide range of critical biological materials for the global diagnostics industry, including antigens for immunoassays and its Quality Laboratory Assessment Products (QAPs™) that support clinical laboratory proficiency testing, enable the development and validation of tests, or help ensure the quality of clinical diagnosis. workflow. Microbix antigens enable antibody testing from more than 100 international diagnostic companies, while its QAPs are sold to clinical laboratory accreditation bodies, diagnostic companies and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA., Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG , SDT Molecular Pte Ltd, Seegene Canada Inc. and Thomas Scientific LLC. Microbix is ​​ISO 9001 and 13485 accredited, registered with the US FDA, registered with the Australian TGA, approved by Health Canada and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, including Viral Transport Medium (DxTM™) to stabilize patient samples for molecular diagnostic laboratory testing and Kinlytic® urokinase, a biological thrombolytic drug used to treat blood clots. Microbix is ​​listed on the TSX and OTCQX and is headquartered in Mississauga, Ontario, Canada.

Forward-looking information
This press release contains “forward-looking information”, as that term is defined in applicable securities laws. Forward-looking information includes, but is not limited to, EUROGIN’s discussion, poster or relevance, Microbix or its associates’ products, Microbix’s business activities and results, its objectives or prospects, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including controlling costs, quality, quantity and delivery times), foreign currencies and exchange rates, maintaining adequate working capital or raising additional capital on acceptable terms or not at all, and other similar statements regarding anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. All statements are made as of the date of this press release and represent the judgment of the Company as of the date of this new press release, and the Company undertakes no obligation to update or change any forward-looking information.

Please visit https://microbix.com or www.sedar.com for the latest Microbix news and filings.

For more information, please contact Microbix at:

Cameron Groome,
(905) 361-8910

Jim Currie,
(905) 361-8910

Deborah Honig,
Investor Relations
Adelaide Capital Markets
(647) 203-8793 ir@microbix.com

Jim McDonald,
Investor Relations
Capital of the Torrey Hills
(858) 456-7300

Copyright © 2022 Microbix Biosystems Inc.
Microbix®DxTM™, kinlytic®PROCEEDx™, QAPs™, REDx™ and REDx™ Controls are registered trademarks of Microbix Biosystems Inc.
PROCEEDx™FLOQ® and REDx™FLOQ® are registered trademarks of Microbix Biosystems Inc. in collaboration with Copan Italia SpA
BD Onclarity™ is a trademark of Becton Dickinson and Company or an affiliate.
Copan®FLOQ®and FLOQSwab® are registered trademarks of Copan Italia SpA

Comments are closed.